The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: A report of three cases;O desafio do tratamento da tuberculose extensivamente resistente em um hospital de referência no estado de São Paulo: Um relato de três casos

Jornal Brasileiro de Pneumologia

Volumn 41, Issue 6, 2015, Pages 554-559

  Arbex, Marcos Abdo ^a,b   de Siqueira, Hélio Ribeiro ^c,d   D’Ambrosio, Lia ^e,f   Migliori, Giovanni Battista ^e  

^a Hospital Nestor Goulart Reis   (Brazil)

^b Centro Universitario de Araraquara   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^e IRCCS   (Italy)

^f Public Health Consulting Group SAGL   (Switzerland)

Author keywords

Antibiotics; Antitubercular; Antitubercular agents; Extensively drug resistant tuberculosis; Multidrug resistant; Tuberculosis

Indexed keywords

IMIPENEM; LINEZOLID; TUBERCULOSTATIC AGENT;

ADULT; BRAZIL; CASE REPORT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HOSPITALIZATION; HUMAN; MALE;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HOSPITALIZATION; HUMANS; IMIPENEM; LINEZOLID; MALE;

EID: 84955086706     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37562015000000299     Document Type: Article

References (14)

1. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
2. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013; 42(1): 156-68. http: //dx. doi. org/10. 1183/09031936. 00134712
3. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013; 42(1): 169-79. http: //dx. doi. org/10. 1183/09031936. 00136312
4. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013; 8(1): e54587. http: //dx. doi. org/10. 1371/journal. pone. 0054587
5. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014; 43(2): 554-65. http: //dx. doi. org/10. 1183/09031936. 00079413
6. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis. 2009; 9(1): 19-30. http: //dx. doi. org/10. 1016/S1473-3099(08)70260-3
7. Brasil. Ministério da Saúde. Secretaria em Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Programa Nacional de Controle da Tuberculose. Nota técnica sobre as mudanças no tratamento da tuberculose no Brasil para adultos e adolescentes-Versão 2. Brasília: Ministério da Saúde; 2009
8. Zumla A, Chalaya K, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015; 3(3): 220-34. http: //dx. doi. org/10. 1016/S2213-2600(15)00063-6
9. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38(3): 516-28. http: //dx. doi. org/10. 1183/09031936. 00073611
10. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013; 56(6): 770-6. http: //dx. doi. org/10. 1093/cid/cis1008
11. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014; 59(1): 9-15. http: //dx. doi. org/10. 1093/cid/ciu209
12. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013; 41(6): 1386-92. http: //dx. doi. org/10. 1183/09031936. 00124312
13. Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, et al. Ertapenem in the treatment of MDR-TB: first clinical experience. Eur Respir J. 2015 Nov 19. pii: ERJ-01278-2015. [Epub ahead of print]
14. Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013; 42(6): 1614-21. http: //dx. doi. org/10. 1183/09031936. 00001913